• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    InMode Reports Fourth Quarter and Full Year 2024 Financial Results; Board of Directors Has Approved a New Share Repurchase Program

    2/4/25 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $INMD alert in real time by email

    Quarterly GAAP revenues of $97.9 million and full year revenue of $394.8 million

    Returned $285.4 million of capital to shareholders in full year 2024 

    Together with new 10% program, represents repurchase of approximately 27% of shares outstanding within 15 month timeframe, with the potential of substantial additional capital return in 2025

    YOKNEAM, Israel, Feb. 4, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the fourth quarter and full year 2024.

    InMode Logo (PRNewsfoto/InMode)

    Fourth Quarter 2024 Highlights:

    • Quarterly GAAP revenues of $97.9 million, compared to $126.8 million in the fourth quarter of 2023.
    • Quarterly revenues from consumables and service of $19.9 million, a decrease of 3% compared to the fourth quarter of 2023.
    • GAAP operation income of $27.9 million, *non-GAAP operation income of $31.3 million.
    • Returned $119.8 million of capital to shareholders through repurchase of ordinary shares.
    • Total cash position of $596.5 million as of December 31, 2024, including cash and cash equivalents, marketable securities and short-term bank deposits.

    Full Year 2024 Highlights:

    • Full year revenues of $394.8 million, a year-over-year decrease of 20%.
    • Full year revenues from consumables and service of $79.3 million, a decrease of 1% compared to 2023.
    • GAAP operation income of $112.5 million, compared to $195.7 million in 2023; record *non-GAAP operation income of $129.1 million, compared to $219.3 million in 2023.
    • Returned $285.4 million of capital to shareholders through repurchase of ordinary shares.

    U.S. GAAP Results

    (U.S. dollars in thousands, except for per share data)



    Q4 2024

    Q4 2023

    FY 2024

    FY 2023

    Revenues

    $97,853

    $126,781

    394,818

    $492,048

    Gross Margins

    79 %

    84 %

    80 %

    84 %

    Net Income

    $82,771

    $55,165

    $181,275

    $197,919

    Earnings per Diluted Share

    $1.14

    $0.64

    $2.25

    $2.30

    *Non-GAAP Results

    (U.S. dollars in thousands, except for per share data)



    Q4 2024 

    Q4 2023

    FY 2024

    FY 2023

    Gross Margins

    80 %

    84 %

    81 %

    84 %

    Net Income

    $31,081

    $61,487

    $142,707

    $221,519

    Earnings per Diluted Share

    $0.42

    $0.71

    $1.76

    $2.57

    *Please refer to "Use of non-GAAP Financial Measures" below for important information about non-GAAP financial measures. A reconciliation between U.S. GAAP and non-GAAP Statement of Income is provided following the financial statements included in this release. Non-GAAP results exclude share-based compensation and tax benefit adjustments.

    Management Comments

    "While we have a solid market position, our fourth quarter results were impacted by stronger than expected headwinds in the aesthetics industry that were intensified by broader macroeconomic challenges," said Moshe Mizrahy, Chief Executive Officer of InMode. "We have taken decisive actions to navigate this environment, and also ensure we're well positioned to benefit when market conditions recover. To that end, we remain committed to leading through innovation. Our recently launched Ignite and OptimasMAX platforms are in the early stages of generating revenue, and we expect to see greater traction from customers as the year progresses. In 2025, we also plan to launch two new platforms targeting the medical aesthetic and wellness markets, where we see opportunity. Thanks to the efforts of our global team, we remain steadfast in delivering excellent support and innovative technologies to our customers."

    Yair Malca, Chief Financial Officer of InMode, added, "The strength of our balance sheet provides us the financial flexibility to evaluate the optimal path to allocate capital to drive enhanced shareholder value. We are pleased to report that during the fourth quarter of 2024, we completed our fourth share repurchase program that was originally announced in September 2024, repurchasing 7.68 million shares for $135 million, out of which $120 million was repurchased during the fourth quarter of 2024. Our total capital return to shareholders for fiscal year 2024 was more than $285 million, executed via share repurchases representing approximately 19% of our share capital and more than double our fiscal year 2024 free cash flow.

    On February 3rd, our Board of Directors approved another tax-efficient share repurchase program of up to 10% of our total shares outstanding, expected to be executed over the next three to six months. Together with our 2024 share repurchases, this represents approximately 27% of share capital to be bought within less than 15 months.

    Given the strength of our free cash flow and confidence in our business, we are also exploring, in consultation with financial, legal and tax advisors, returning significant additional capital by the end of the year to create further shareholder value. We will continue to carefully review and evaluate our approach to capital allocation, with a focus on ensuring we deliver enhanced value for all shareholders and will continue our dialogue with shareholders on this important process."

    Fourth Quarter and Full Year 2024 Financial Results

    Total GAAP revenues for the fourth quarter of 2024 were $97.9 million, a decrease of 23% compared to $126.8 million in the fourth quarter of 2023. Total revenues for 2024 were $394.8 million, a decrease of 20% compared to 2023.

    GAAP gross margin for the fourth quarter of 2024 was 79%, compared to 84% for the fourth quarter of 2023. *Non-GAAP gross margin for the fourth quarter of 2024 was 80%, compared to 84% for the fourth quarter of 2023. GAAP gross margin for 2024 was 80%, compared to 84% for 2023. *Non-GAAP gross margin for 2024 was 81%, compared to 84% for 2023.

    GAAP operating margin for the fourth quarter of 2024 was 28%, compared to 40% in the fourth quarter of 2023. *Non-GAAP operating margin for the fourth quarter of 2024 was 32%, compared to 45% for the fourth quarter of 2023. GAAP operating margin for 2024 was 29%, compared to 40% in 2023. *Non-GAAP operating margin for 2024 was 33%, compared to 45% in the full year of 2023. This decrease was primarily attributable to higher sales and marketing expenses, primarily a result of recent management changes, as well as additional investments in trade shows and workshop activities.

    InMode reported GAAP net income of $82.8 million, or $1.14 per diluted share, in the fourth quarter of 2024, compared to $55.2 million, or $0.64 per diluted share, in the fourth quarter of 2023. On a *non-GAAP basis, InMode reported net income of $31.1 million, or $0.42 per diluted share, in the fourth quarter of 2024, compared to $61.5 million, or $0.71 per diluted share, in the fourth quarter of 2023. GAAP net income was $181.3 million, or $2.25 per diluted share, in 2024, compared to GAAP net income of $197.9 million, or $2.30 per diluted share, in 2023. On a *non-GAAP basis, InMode reported net income of $142.7 million, or $1.76 per diluted share, in the full year of 2024, compared to net income of $221.5 million, or $2.57 per diluted share, for the full year in 2023.

    As of December 31, 2024, InMode had cash and cash equivalents, marketable securities and short-term bank deposits of $596.5 million.

    As of December 31, 2024, the Company's U.S. subsidiary has an accumulated federal tax loss carryforward of approximately $203 million and a state tax loss carryforward of approximately $165.5 million, primarily arising from employee stock option exercises that generated tax deductions exceeding recognized compensation expenses. After assessing cumulative income in recent years and the realizability of deferred tax assets, the Company released a valuation allowance related to its U.S. net deferred tax assets, and as a result recorded a deferred tax asset of $55.1 million.

    2025 Financial Outlook

    Management provided an outlook for the full year of 2025 ending December 31, 2025. Based on our current estimates, management expects:

    • Revenues between $395 to $405 million
    • *Non-GAAP gross margin between 80% and 82%
    • *Non-GAAP income from operations to be between $130 million and $135 million
    • *Non-GAAP earnings per diluted share between $1.95 to $1.99

    This outlook is not a guarantee of future performance, and stockholders should not rely on such forward-looking statements. See "Forward-Looking Statements" for additional information.

    *Please refer to "Use of non-GAAP Financial Measures" below for important information about non-GAAP financial measures. A reconciliation between U.S. GAAP and non-GAAP Statement of Income is provided following the financial statements that are included in this release. Non-GAAP results exclude share-based compensation and tax benefit adjustments.

    However, these estimates are based on management's current estimates, which may be updated. 

    The Current Situation in Israel

    Regarding the current situation in Israel, Israel and Hamas recently agreed to a ceasefire agreement, the first phase of such ceasefire began on January 19, 2025. With the ceasefire agreement in place, we remain confident in our ability to continue our R&D and manufacturing activities while maintaining the safety and well-being of our employees.

    Use of Non-GAAP Financial Measures

    In addition to InMode's operating results presented in accordance with GAAP, this release contains certain non-GAAP financial measures including non-GAAP net income, non-GAAP earnings per diluted share, non-GAAP operating margin. Because these measures are used in InMode's internal analysis of financial and operating performance, management believes they provide investors with greater transparency of its view of InMode's economic performance. Management also believes the presentation of these measures, when analyzed in conjunction with InMode's GAAP operating results, allows investors to more effectively evaluate and compare InMode's performance to that of its peers, although InMode's presentation of its non-GAAP measures may not be strictly comparable to the similarly titled measures of other companies. Schedules reconciling each of these non-GAAP financial measures are provided as a supplement to this release.

    Conference Call Information

    Mr. Moshe Mizrahy, Chief Executive Officer, Dr. Michael Kreindel, Co-Founder and Chief Technology Officer and Mr. Yair Malca, Chief Financial Officer, will host a conference call today, February 4, 2025, at 8:30 a.m. Eastern Time to discuss the fourth quarter and full year 2024 financial results.

    The Company encourages participants to pre-register for the conference call using the following link: 

    https://dpregister.com/sreg/10195703/fe3de01ec4.

    Callers will receive a unique dial-in number upon registration, which enables immediate access to the call. Participants may pre-register at any time, including up to and after the call start time.

    For callers who opt out of pre-registration, please dial one of the following teleconferencing numbers. Please begin by placing your call 10 minutes before the conference call commences. If you are unable to connect using the toll-free number, please try the international dial-in number.

    U.S. Toll-Free Dial-in Number: 1-833-316-0562

    Israel Toll- Free Dial-in Number: 1-80-921-2373

    International Dial-in Number: 1-412-317-5736

    Webcast URL: https://event.choruscall.com/mediaframe/webcast.html?webcastid=4AkhyaPz

    At:

    8:30 a.m. Eastern Time

    5:30 a.m. Pacific Time

    The conference call will also be webcast live from a link on InMode's website at https://inmodemd.com/investors/events-presentations/. A replay of the conference call will be available from February 4, 2025, at 12 p.m. Eastern Time to February 13, 2025, at 11:59 p.m. Eastern Time. To access the replay, please dial one of the following numbers: 

    Replay Dial-in U.S TOLL-FREE: 1-877-344-7529

    Replay Dial-in Canada TOLL-FREE: 855-669-9658

    Replay Dial-in TOLL/INTERNATIONAL: 1-412-317-0088

    Replay Pin Number: 4023671

    To access the replay using an international dial-in number, please select the link below: 

    https://services.choruscall.com/ccforms/replay.html

    A replay of the conference call will also be available for 90 days on InMode's website at https://inmodemd.com/investors/.

    About InMode

    InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio frequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.

    Forward-Looking Statements 

    The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or InMode's future financial or operating performance, including the 2025 revenue projection described above. Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would" and similar expressions that concern our expectations, strategic plans or intentions. Forward-looking statements are based on management's current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Consequently, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode's Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 04, 2025, and our future public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which pertain only as of the date of this press release.

     

    Company Contact:

    Yair Malca

    Chief Financial Officer

    Phone: (949) 305-0108

    Email: [email protected]

    Investor Relations Contact:

    Miri Segal

    MS-IR LLC

    Email: [email protected]

     

     

     

    INMODE LTD.

    CONDENSED CONSOLIDATED STATEMENTS OF INCOME

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)



    Three months ended

    December 31,

    Year Ended

    December 31,



    2024

    2023

    2024

    2023



    REVENUES

    97,853

    126,781

    394,818

    492,048



    COST OF REVENUES

    20,216

    20,264

    77,752

    80,708



    GROSS PROFIT

    77,637

    106,517

    317,066

    411,340



    OPERATING EXPENSES:











    Research and development

    2,667

    3,473

    13,137

    13,410



    Sales and marketing

    44,653

    49,451

    181,366

    193,042



    General and administrative

    2,453

    2,349

    10,032

    9,228



    TOTAL OPERATING EXPENSES

    49,773

    55,273

    204,535

    215,680



    OPERATIONS INCOME

    27,864

    51,244

    112,531

    195,660



    Finance income, net

    4,346

    8,920

    30,938

    21,607



    INCOME BEFORE INCOME TAXES

    32,210

    60,164

    143,469

    217,267



    INCOME TAXES BENEFIT (EXPENSES)

    50,561

    (4,999)

    37,806

    (19,348)



    NET INCOME

    82,771

    55,165

    181,275

    197,919















    EARNINGS PER SHARE:











    Basic

    1.15

    0.66

    2.29

    2.37



    Diluted

    1.14

    0.64

    2.25

    2.30



    WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF EARNINGS PER SHARE (in thousands)











    Basic

    71,874

    83,862

    79,306

    83,534



    Diluted

    72,787

    85,835

    80,597

    85,954



     

     

    INMODE LTD.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)



    December 31,

    2024

    December 31,

    2023

    Assets





    CURRENT ASSETS:





    Cash and cash equivalents

    155,329

    144,411

    Marketable securities (amortized cost of $268,129 and $375,829, as of December 31, 2024 and 2023, respectively)

    267,688

    373,647

    Short-term bank deposits

    173,455

    223,547

    Accounts receivable, net of allowance for credit losses of $1,825 and $1,538, as of December 31, 2024 and 2023, respectively

    36,335

    42,362

    Prepaid expense and other receivables

    22,097

    16,268

    Inventories

    59,548

    45,095

             TOTAL CURRENT ASSETS

    714,452

    845,330

        NON-CURRENT ASSETS:





    Accounts receivable, net of allowance for credit losses of $924 and $716 as of December 31, 2024 and 2023, respectively

    3,176

    3,670

    Deferred income tax asset

    56,285

    1,506

    Operating lease right-of-use assets

    8,732

    9,698

    Property and equipment, net

    2,322

    2,382

    Other investments

    700

    700

    TOTAL NON-CURRENT ASSETS

    71,215

    17,956

    TOTAL ASSETS

    785,667

    863,286

    Liabilities and shareholders' equity





    CURRENT LIABILITIES:





    Accounts payable

    13,782

    13,966

    Contract liabilities

    16,755

    10,923

    Other liabilities

    39,314

    39,247

    TOTAL CURRENT LIABILITIES

    69,851

    64,136

        NON-CURRENT LIABILITIES:





    Contract liabilities

    3,336

    3,766

    Other liabilities

    3,356

    1,399

    Operating lease liabilities

    5,311

    6,613

    TOTAL NON-CURRENT LIABILITIES

    12,003

    11,778

    TOTAL LIABILITIES

    81,854

    75,914







    TOTAL SHAREHOLDERS' EQUITY

    703,813

    787,372

    TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

    785,667

    863,286

     

     

    INMODE LTD.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)





    Three months ended

    December 31,

    Year Ended

    December 31,



    2024

    2023

    2024

    2023



    CASH FLOWS FROM OPERATING ACTIVITIES:











    Net income

    82,771

    55,165

    181,275

    197,919



    Adjustments required to reconcile net income to net cash provided by operating activities:











    Depreciation and amortization

    248

    122

    728

    623



    Share-based compensation expenses

    3,447

    6,322

    16,569

    23,600



    Change in allowance for credit losses of trade receivable

    158

    355

    572

    1,020



    Loss (Gain) on marketable securities, net

    (3)

    -

    167

    -



    Finance expenses (income), net

    1,533

    (1,581)

    (4,401)

    (4,714)



    Deferred income tax assets, net

    (55,121)

    (30)

    (55,179)

    (184)



    Changes in operating assets and liabilities:











    Decrease (increase) in accounts receivable (current and non-current)

    4,025

    377

    5,949

    (16,084)



    Decrease (increase) in other receivables

    1,879

    3,143

    (5,698)

    (2,224)



    Increase in inventories

    (1,264)

    (5,106)

    (14,453)

    (5,198)



    Increase (decrease) in accounts payable

    (531)

    1,633

    (184)

    (2,276)



    Increase (decrease) in other liabilities

    (4,243)

    204

    1,917

    (12,588)



    Increase (decrease) in contract liabilities (current and non-current)

    (457)

    562

    5,402

    (3,068)



    Net cash provided by operating activities

    32,442

    61,166

    132,664

    176,826



    CASH FLOWS FROM INVESTING ACTIVITIES:











       Investment in short-term deposits

    (3,500)

    (67,101)

    (168,187)

    (233,241)



       Proceeds from short-term deposits

    67,100

    -

    218,740

    85,090



       Purchase of fixed assets

    (234)

    (21)

    (669)

    (705)



       Other investments

    -

    (100)

    -

    (100)



       Purchase of marketable securities

    (59,708)

    (52,527)

    (336,221)

    (245,337)



       Proceeds from sale of marketable securities

    21,146

    5,000

    90,754

    5,000



       Proceeds from maturity of marketable securities

    53,012

    63,159

    357,789

    253,229



    Net cash provided by (used in) investing activities

    77,816

    (51,590)

    162,206

    (136,064)



    CASH FLOWS FROM FINANCING ACTIVITIES:











      Repurchase of ordinary shares

    (119,849)

    -

    (285,385)

    -



           Exercise of options

    1,420

    275

    2,614

    5,504



    Net cash provided by (used in) financing activities

    (118,429)

    275

    (282,771)

    5,504



    EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS

    (1,338)

    827

    (1,181)

    605



    NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

    (9,509)

    10,678

    10,918

    46,871



    CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR                       

    164,838

    133,733

    144,411

    97,540



    CASH AND CASH EQUIVALENTS AT END OF YEAR

    155,329

    144,411

    155,329

    144,411



     

     

    INMODE LTD.

    CONDENSED CONSOLIDATED FINANCIAL HIGHLIGHTS

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)



    Three months ended December 31,

    Year ended December 31,

    2024

    2023

    2024

    2023

    Revenues by Category:



































    Capital Equipment revenues - United States

    53,128

    55 %

    69,253

    55 %

    204,520

    52 %

    260,801

    53 %

    Capital Equipment revenues - International

    24,836

    25 %

    37,004

    29 %

    111,027

    28 %

    151,288

    31 %

    Total Capital Equipment revenues

    77,964

    80 %

    106,257

    84 %

    315,547

    80 %

    412,089

    84 %

    Consumables and service revenues

    19,889

    20 %

    20,524

    16 %

    79,271

    20 %

    79,959

    16 %

    Total Revenue

    97,853

    100 %

    126,781

    100 %

    394,818

    100 %

    492,048

    100 %

























     

     



    Three months ended December 31,

    Year ended December 31,

    2024

    2023

    2024

    2023



    %

    %

    %

    %



    United States

    International

    Total

    United States

    International

    Total

    United States

    International

    Total

    United States

    International

    Total

    Revenues by Technology:

























    Minimal-Invasive

    93

    76

    86

    84

    80

    83

    92

    80

    87

    86

    77

    83

    Hands-Free

    5

    3

    5

    12

    4

    9

    6

    3

    5

    11

    5

    8

    Non-Invasive

    2

    21

    9

    4

    16

    8

    2

    17

    8

    3

    18

    9



    100

    100

    100

    100

    100

    100

    100

    100

    100

    100

    100

    100

     

    INMODE LTD.

    RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF

     INCOME TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF INCOME 

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)







     

     

    Three months ended December 31, 2024

     

    Three months ended December 31, 2023

     

     

     

    GAAP

     

     

    Share Based

    Compensation

     

     

     

    Tax benefit (1)

     

     

     

    Non-GAAP

     

     

     

    GAAP

     

     

    Share Based

    Compensation

     

     

     

    Non-GAAP

    REVENUES

    97,853

    -

    -

    97,853

    126,781

    -

    126,781

    COST OF REVENUES

    20,216

    (472)

    -

    19,744

    20,264

    (573)

    19,691

    GROSS PROFIT

    77,637

    472

    -

    78,109

    106,517

    573

    107,090

    OPERATING EXPENSES:















    Research and development

    2,667

    (300)

    -

    2,367

    3,473

    (665)

    2,808

    Sales and marketing

    44,653

    (2,360)

    -

    42,293

    49,451

    (4,611)

    44,840

    General and administrative

    2,453

    (315)

    -

    2,138

    2,349

    (473)

    1,876

    TOTAL OPERATING

    EXPENSES

     

    49,773

     

    (2,975)

     

    -

     

    46,798

     

    55,273

    (5,749)

    49,524

    OPERATIONS INCOME

    27,864

    3,447

    -

    31,311

    51,244

    6,322

    57,566

    Finance income, net

    4,346

    -

    -

    4,346

    8,920

    -

    8,920

    INCOME BEFORE INCOME TAXES

    32,210

    3,447

    -

    35,657

    60,164

    6,322

    66,486

    INCOME TAXES BENEFIT (EXPENSES)

     

    50,561

     

    -

     

    (55,137)

     

    (4,576)

     

    (4,999)

    -

    (4,999)

    NET INCOME

    82,771

    3,447

    (55,137)

    31,081

    55,165

    6,322

    61,487

















    EARNINGS PER SHARE:















    Basic

     

    1.15





     

    0.43

     

    0.66



    0.73

    Diluted

    1.14





    0.42

    0.64



    0.71

    WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF EARNINGS PER SHARE (in thousands)















    Basic

    71,874





    71,874

    83,862



    83,862

    Diluted

    72,787





    73,139

    85,835



    86,196

     

    (1) Tax benefit recorded during the year ended December 31, 2024, as a result of a release of valuation allowance on our deferred tax assets in the United States as it is more likely than not that our net deferred tax assets will be realized given our expectation of profitability in future periods.

     



    Year Ended December 31, 2024

    Year Ended December 31, 2023

    GAAP

    Share Based

    Compensation

     

     

    Tax benefit (1)

    Non-GAAP

    GAAP

    Share Based

    Compensation

    Non-GAAP

    REVENUES

    394,818

    -

    -

    394,818

    492,048

    -

    492,048

    COST OF REVENUES

    77,752

    (1,833)

    -

    75,919

    80,708

    (2,046)

    78,662

    GROSS PROFIT

    317,066

    1,833

    -

    318,899

    411,340

    2,046

    413,386

    OPERATING EXPENSES:















    Research and development

    13,137

    (2,177)

    -

    10,960

    13,410

    (2,652)

    10,758

    Sales and marketing

    181,366

    (11,367)



    169,999

    193,042

    (17,167)

    175,875

    General and administrative

    10,032

    (1,192)

    -

    8,840

    9,228

    (1,735)

    7,493

    TOTAL OPERATING

    EXPENSES

    204,535

    (14,736)

     

    -

    189,799

    215,680

    (21,554)

     

    194,126

    OPERATIONS INCOME

    112,531

    16,569

    -

    129,100

    195,660

    23,600

     

    219,260

    Finance income, net

    30,938

    -

    -

    30,938

    21,607

    -

    21,607

    INCOME BEFORE INCOME TAXES

    143,469

    16,569

    -

    160,038

    217,267

    23,600

    240,867

    INCOME TAXES BENEFIT (EXPENSES)

    37,806

    -

     

    (55,137)

    (17,331)

    (19,348)

    -

    (19,348)

    NET INCOME

    181,275

    16,569

    (55,137)

    142,707

    197,919

    23,600

    221,519

















    EARNINGS PER

    SHARE:















    Basic

    2.29





    1.80

    2.37



    2.65

    Diluted

    2.25





    1.76

    2.30



    2.57

    WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF EARNINGS PER SHARE (in thousands)















    Basic

    79,306





    79,306

    83,534



    83,534

    Diluted

    80,597





    80,943

    85,954



    86,177

     

    (1) Tax benefit recorded during the year ended December 31, 2024, as a result of a release of valuation allowance on our deferred tax assets in the United States as it is more likely than not that our net deferred tax assets will be realized given our expectation of profitability in future periods.

    Logo - https://mma.prnewswire.com/media/1064477/5147938/InMode_Logo.jpg

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/inmode-reports-fourth-quarter-and-full-year-2024-financial-results-board-of-directors-has-approved-a-new-share-repurchase-program-302366770.html

    SOURCE InMode LTD.

    Get the next $INMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INMD

    DatePrice TargetRatingAnalyst
    4/29/2025Buy → Neutral
    BTIG Research
    4/28/2025$22.00 → $16.00Outperform → Neutral
    Robert W. Baird
    10/17/2024$25.00Buy
    BTIG Research
    7/23/2024$21.00 → $19.00Buy → Hold
    Jefferies
    11/3/2023$52.00 → $24.00Buy → Neutral
    UBS
    10/13/2023$55.00 → $22.00Buy → Hold
    Canaccord Genuity
    3/29/2023$40.00Buy
    UBS
    2/17/2023Buy → Hold
    Needham
    More analyst ratings

    $INMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    InMode downgraded by BTIG Research

    BTIG Research downgraded InMode from Buy to Neutral

    4/29/25 8:06:22 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded InMode from Outperform to Neutral and set a new price target of $16.00 from $22.00 previously

    4/28/25 1:56:11 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BTIG Research initiated coverage on InMode with a new price target

    BTIG Research initiated coverage of InMode with a rating of Buy and set a new price target of $25.00

    10/17/24 7:41:34 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InMode Reports Third Quarter 2025 Financial Results: Quarterly Revenue of $93.2 Million, 78% Gross Margins

    YOKNEAM, Israel, Nov. 5, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights: Quarterly GAAP revenues of $93.2 million, compared to $130.2 million in the third quarter of 2024, which included $31.9 million of pre-order sales.Quarterly revenues from consumables and service of $19.9 million, an increase of 26% compared to the third quarter of 2024.GAAP operating income of $20.9 million. *Non-GAAP operating income was $23.6 million.Total cash position of $532.3 million as of September 30, 2025, incl

    11/5/25 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode Appoints Michael Dennison as President of North America

    IRVINE, Calif., Nov. 3, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, has appointed Michael Dennison, most recently Vice President of Sales, as President of North America.  Dennison has held nearly every sales position in the aesthetic medical device industry, consistently producing at the highest level in each. With close to a decade of leadership experience at InMode, Dennison has advanced through roles from District Sales Manager to Vice President of Sales, driving national revenue growth, expanding market shar

    11/3/25 8:05:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode to Participate in Upcoming Investor Conferences

    YOKNEAM, Israel, Oct. 30, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced the participation in the following investor conferences in November: UBS Global Healthcare Conference Presenter: Yair Malca, Chief Financial Officer Format: In-person one-on-one meetings Location: Palm Beach Gardens, FL When: Monday, November 10 Jefferies Global Healthcare Conference Presenter: Moshe Mizrahy, Chief Executive Officer Format: In-person fireside chat moderated by Matt Taylor, Senior Equity Analyst, and one-on-one meetings Location: London, U.K. When: Tuesday, November 18, Fireside Chat at 4:00 pm GMT A live webcast of the prese

    10/30/25 8:30:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    SEC Filings

    View All

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    11/5/25 7:00:08 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    9/18/25 7:30:09 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    7/30/25 7:01:14 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

    SC 13G/A - InMode Ltd. (0001742692) (Subject)

    2/13/24 4:31:18 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

    SC 13G/A - InMode Ltd. (0001742692) (Subject)

    2/13/24 4:25:40 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by InMode Ltd.

    SC 13G - InMode Ltd. (0001742692) (Subject)

    2/6/24 9:36:39 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Financials

    Live finance-specific insights

    View All

    InMode Reports Third Quarter 2025 Financial Results: Quarterly Revenue of $93.2 Million, 78% Gross Margins

    YOKNEAM, Israel, Nov. 5, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights: Quarterly GAAP revenues of $93.2 million, compared to $130.2 million in the third quarter of 2024, which included $31.9 million of pre-order sales.Quarterly revenues from consumables and service of $19.9 million, an increase of 26% compared to the third quarter of 2024.GAAP operating income of $20.9 million. *Non-GAAP operating income was $23.6 million.Total cash position of $532.3 million as of September 30, 2025, incl

    11/5/25 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode to Report Third Quarter 2025 Financial Results and Hold Conference Call on November 5, Expects Q3 Revenue Between $92.5M-$93.0M, Reiterates FY 2025 Guidance Between $365M-$375M

    Conference call to be held on Wednesday, November 5, 2025, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Oct. 9, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the third quarter 2025 before the Nasdaq market opens on Wednesday, November 5, 2025. InMode is currently finalizing its financial results for the third quarter of 2025. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of InMode's financial results for such period, subject to final adjustments and other developments that may aris

    10/9/25 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Return Capital to the Shareholders

    Believes the Board Should Approve and Execute a 10% Buyback in Q4 2025 and Another 10% Buyback in Q1 2026 Maintains Board Has Legal and Fiduciary Duty to Act in Best Interests of Shareholders  MIAMI, Sept. 9, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode"), today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to return capital to shareholders.  The letter can be downloaded here The full text of the letter follows: September 9th, 2025 To the Board Members of InMode: In

    9/9/25 8:15:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Leadership Updates

    Live Leadership Updates

    View All

    InMode Appoints Michael Dennison as President of North America

    IRVINE, Calif., Nov. 3, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, has appointed Michael Dennison, most recently Vice President of Sales, as President of North America.  Dennison has held nearly every sales position in the aesthetic medical device industry, consistently producing at the highest level in each. With close to a decade of leadership experience at InMode, Dennison has advanced through roles from District Sales Manager to Vice President of Sales, driving national revenue growth, expanding market shar

    11/3/25 8:05:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care